Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases

  • Park, Soo-Kyung
  • Choi, Chang Hwan
  • Chun, Jaeyoung
  • Lee, Heeyoung
  • Kim, Eun Sun
  • 외 8명
Citations

WEB OF SCIENCE

19
Citations

SCOPUS

18

초록

The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host's immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.

키워드

Inflammatory bowel diseaseViral hepatitisVaccinationPreventionB-VIRUS REACTIVATIONSTEM-CELL TRANSPLANTATIONA VACCINEHBV REACTIVATIONCANCER-PATIENTSCYTOTOXIC CHEMOTHERAPYIMMUNIZATION PRACTICESRHEUMATOID-ARTHRITISGLOBAL EPIDEMIOLOGYBOOSTER VACCINATION
제목
Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
저자
Park, Soo-KyungChoi, Chang HwanChun, JaeyoungLee, HeeyoungKim, Eun SunPark, Jae JunPark, Chan HyukLee, Bo-InJung, YunhoPark, Dong-IlKim, Do YoungPark, HanaJeen, Yoon Tae
DOI
10.5217/ir.2019.09155
발행일
2020-01
유형
Review
저널명
Intestinal research
18
1
페이지
18 ~ 33

파일 다운로드